firms. Formerly he was CEO of Lab Velocity, Inc., and Internet information portal for the life sciences research community. Prior to that, he was CEO of Berkshire Holding Corporation, a privately-held, multinational manufacturer of contamination control materials for microelectronics and pharmaceutical production. Bromley’s experience also includes 17 years with American Hospital Supply Corporation and Baxter Healthcare, in both the distribution and diagnostics businesses, culminating with 7 years as president of the Burdick and Jackson Division. Bromley holds a degree in biochemistry from Rice University.
Tricia Brooks is the managing director for alliance development at the Biotechnology Industry Organization (BIO). Ms. Brooks brings more than 15 years of public affairs, patient advocacy, and FDA regulatory experience to the position, building coalitions and partnerships with patient advocacy organizations; local, national, and international business organizations; state and federal government relations, and pharmaceutical and biotechnology communities. Most recently, Ms. Brooks was a principal at WHD Government Affairs, developing and implementing public affairs strategies, managing issue campaigns, and representing a variety of clients in Washington while developing public- and private-sector relationships.
Ms. Brooks was part of the team that successfully integrated Michael J. Fox into national campaigns to raise awareness of the embryonic stem cell research debate. Notably, she was the director of government relations for the Christopher and Dana Reeve Foundation (CDRF). Prior to CDRF, Ms. Brooks advocated policies related to biomedical research, including clinical trials and stem cell research, led issue-based campaigns through broad public education initiatives, mobilized grassroots lobbying, and developed diverse coalitions to advocate with both the legislative and executive branches. Ms. Brooks began her career as a regulatory consultant for pharmaceutical development providing strategic, regulatory, and technical assistance to the pharmaceutical and biotech industry. She has a B.A. in political science from Fordham University and an M.A. in public policy from George Washington University.
Lucie Bruijn, Ph.D., joined the Amyotrophic Lateral Sclerosis (ALS) Association in January 2001 as science director and vice president. Prior to joining the association, Dr. Bruijn led a small team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative disease. Dr. Bruijn received her bachelor’s degree in pharmacy